Guardant Health (NASDAQ:GH) Price Target Lowered to $45.00 at JPMorgan Chase & Co.

Guardant Health (NASDAQ:GH – Free Report) had its target price lowered by JPMorgan Chase & Co. from $60.00 to $45.00 in a research note published on Friday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock. A number of other equities analysts have also recently commented on GH. Guggenheim […]

Related Keywords

United States ,Raymond James ,Kumud Kalia ,Jpmorgan Chase Co ,Guardant Health Stock Performance ,Metlife Investment Management ,Morgan Stanley ,Institutional Investors Weigh In On Guardant Health ,Wolfe Research ,Bridgewater Associates ,First Trust Advisors ,Guardant Health ,Analyst Recommendations For Guardant Health ,Us Bancorp ,News Ratings For Guardant Health Daily ,Canaccord Genuity Group ,Guardant Health Inc ,Vontobel Holding Ltd ,Guardant Health Company Profile ,Free Report ,Genuity Group ,Moderate Buy ,Life Investment Management ,Trust Advisors ,Get Free Report ,Next Test ,Guardant Health Daily ,Nasdaq Gh ,Ugh ,Medical ,Lower Price Target ,